Craft

Seagen

Stock Price

$199.8

2023-08-25

Market Capitalization

$37.5 B

2023-08-25

Revenue

$2 B

FY, 2022

Seagen Summary

Company Summary

Overview
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. It offers ADCETRIS for the treatment of certain CD30-expressing lymphomas; PADCEV for the treatment of certain metastatic urothelial cancers; TUKYSA for the treatment of certain metastatic HER2-positive breast cancers; and TIVDAK for the treatment of certain metastatic cervical cancers.
Type
Public
Status
Active
Founded
1998
HQ
Bothell, WA, US | view all locations
Website
https://www.seagen.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • David R. Epstein

    David R. Epstein, Chief Executive Officer and Director

  • Roger Dansey

    Roger Dansey, President, Research and Development

  • Vaughn Himes

    Vaughn Himes, Chief Technical Officer

  • Todd Simpson

    Todd Simpson, Chief Financial Officer

    LocationsView all

    11 locations detected

    • Bothell, WA HQ

      United States

      21717 30th Drive S.E., Building 3

    • Bothell, WA

      United States

      21823 30th Drive S.E.

    • Mississauga, ON

      Canada

      2000 Argentia Road Plaza 3, Suite 400

    • Hørsholm

      Denmark

      Agern Alle 24

    • Rueil-Malmaison, IDF

      France

      55 Av. de Colmar

    • München, BY

      Germany

      Maximilianstr. 13, 3rd floor

    and 5 others

    Seagen Financials

    Summary Financials

    Revenue (Q2, 2023)
    $603.8M
    Gross profit (Q2, 2023)
    $423.1M
    Net income (Q2, 2023)
    ($211.5M)
    Cash (Q2, 2023)
    $308.4M
    EBIT (Q2, 2023)
    ($220.7M)
    Enterprise value
    $37.3B

    Footer menu